Comparison of Antimetabolite Drugs as Corticosteroid-Sparing Therapy for Noninfectious Ocular Inflammation

Ophthalmology

Volumn 115, Issue 10, 2008, Pages 1826-1832

  Galor, Anat ^a   Jabs, Douglas A ^a,b,c   Leder, Henry A ^a   Kedhar, Sanjay R ^d   Dunn, James P ^a   Peters III, George B ^a   Thorne, Jennifer E ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NEW YORK EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADOLESCENT; ADULT; AGED; AMYLASE BLOOD LEVEL; ANGINA PECTORIS; ANOREXIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMOGRAPHY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE INFLAMMATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SCLERITIS; SIDE EFFECT; UVEITIS; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES; AZATHIOPRINE; CHILD; FEMALE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; MALE; METHOTREXATE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; RETROSPECTIVE STUDIES; SCLERITIS; UVEITIS;

EID: 52949152867     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.04.026     Document Type: Article

References (26)

1. Jabs D.A., and Rosenbaum J.T. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. [letter]. Am J Ophthalmol 131 (2001) 679
2. Yazici H., Pazarli H., Barnes C.G., et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 322 (1990) 281-285
3. Mathews J.D., Crawford B.A., Bignell J.L., and Mackay I.R. Azathioprine in active chronic iridocyclitis: a double-blind controlled trial. Br J Ophthalmol 53 (1969) 327-330
4. Kim E.C., and Foster C.S. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. Int Ophthalmol Clin 46 (2006) 141-164
5. Foeldvari I., and Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 32 (2005) 362-365
6. Shah S.S., Lowder C.Y., Schmitt M.A., et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 99 (1992) 1419-1423
7. Thorne J.E., Jabs D.A., Qazi F.A., et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112 (2005) 1472-1477
8. Samson C.M., Waheed N., Baltatzis S., and Foster C.S. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108 (2001) 1134-1139
9. Baltatzis S., Tufail F., Yu E.N., et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110 (2003) 1061-1065
10. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 140 (2005) 509-516
11. Hoekstra M., Haagsma C., Neef C., et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31 (2004) 645-648
12. Bom S., Zamiri P., and Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm 9 (2001) 35-40
13. Choudhary A., Harding S.P., Bucknall R.C., and Pearce I.A. Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease. J Ocul Pharmacol Ther 22 (2006) 168-175
14. Dev S., McCallum R.M., and Jaffe G.J. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 106 (1999) 111-118
15. Doycheva D., Deuter C., Stuebiger N., et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 91 (2007) 180-184
16. Hamuryudan V., Ozyazgan Y., Hizli N., et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 40 (1997) 769-774
17. Holz F.G., Krastel H., Breitbart A., et al. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1 (1992) 142-144
18. Kaplan-Messas A., Barkana Y., Avni I., and Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 11 (2003) 131-139
19. Larkin G., and Lightman S. Mycophenolate mofetil: a useful immunosuppressive in inflammatory eye disease. Ophthalmology 106 (1999) 370-374
20. Lau C.H., Comer M., and Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 31 (2003) 487-491
21. Malik A.R., and Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol 89 (2005) 806-808
22. Da Silva J.A., Jacobs J.W., Kirwan J.R., et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 65 (2006) 285-293
23. Soheilian M., Aletaha M., Yazdani S., et al. Management of pediatric Vogt-Koyanagi- Harada (VKH)-associated panuveitis. Ocul Immunol Inflamm 14 (2006) 91-98
24. Newell F.W., and Krill A.E. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc U K 87 (1967) 499-511
25. Andrasch R.H., Pirofsky B., and Burns R.P. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 96 (1978) 247-251
26. Kilmartin D.J., Forrester J.V., and Dick A.D. Rescue therapy with mycophenolate mofetil in refractory uveitis. [letter]. Lancet 352 (1998) 35-36